Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention

Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention for Under-served Hispanics

The proposed study will develop and test an implementation strategy called Salud en Mis Manos-Dissemination and Implementation Assistance (SEMM-DIA) which is an internet-accessible cross-platform that includes additional implementation support strategies to increase the reach, effectiveness, and implementation of an evidence-based breast and cervical cancer screening and HPV vaccination program for Latinas (SEMM).

Study Overview

• Status: Not yet recruiting
• Conditions: Cancer Prevention
• Intervention / Treatment: Behavioral: Salud en Mis Manos - Dissemination and Implementation Assistance; Behavioral: Salud en Mis Manos- Usual Implementation Practice

Detailed Description

This study tests a multicomponent and multifaceted implementation strategy, SEMM-DIA and serves as a model for developing other implementation strategies designed to build the capacity of clinic leadership, intervention champions, and LHWs to plan, manage, and deliver SEMM. Investigators will examine the effect of SEMM-DIA program implementation in a randomized group trial comparing the impact of SEMM-DIA vs. SEMM- Usual Implementation Practice on the reach, effectiveness, implementation, and cost-effectiveness of SEMM in safety-net clinics.

• Study Type: Interventional
• Enrollment (Estimated): 2000
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Lara Savas, PhD; Phone Number: (713) 500-9638; Email: lara.staub@uth.tmc.edu
• Study Contact Backup: Name: Angelita Alaniz, MPH; Email: angelita.alaniz@uth.tmc.edu

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • The University of Texas Health Science Center at Houston
      • Contact: Angelita Alaniz, MPH; Email: angelita.alaniz@uth.tmc.edu
      • Contact: Lara Savas, PhD; Phone Number: 713-500-9638; Email: lara.staub@uth.tmc.edu
      • Principal Investigator: Maria E Fernandez, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 21 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Organization inclusion criteria:

• Clinic or community health center (CHC) with LHWs serving Latina populations.
• Expressed intent to participate in the implementation of SEMM.
• Serve low-income populations with low or no-cost screening and vaccination.
• Provide comprehensive primary health care services.

SEMM Participant Inclusion criteria:

• Latinas who self-identify as Hispanic/Latina.
• Latinas who have at least one unmet breast or cervical cancer prevention need, following Electronic Clinical Quality Measures.
• (1) Latinas aged 21-64 years who have not had a Pap test in the past 3 years, and (2) Latinas aged 30-64 who have not had a HPV test in the past 5 years (CMS eCQM ID: CMS124v9).
• (3) Latinas aged 51-74 years who have not had a mammogram in the past 2 years (CMS eCQM ID: CMS125v9).

• (4) Latinas aged 18-26 years who have not initiated HPV vaccination.

  • Note: Some women will have more than one unmet need (e.g., HPV vaccination and pap test), so they will be included in more than one non-adherent group.

Exclusion Criteria:

Organization exclusion criteria:

- Clinics/Community Health Centers not located in Texas.

SEMM Participant Exclusion criteria:

- Latinas with a prior or current cancer diagnosis due to modified cancer screening surveillance guidelines for cancer survivors.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Salud en Mis Manos - Dissemination and Implementation Assistance; The multi-component and multi-faceted implementation strategy SEMM-DIA	Behavioral: Salud en Mis Manos - Dissemination and Implementation Assistance; The experimental arm will utilize the multi-component and multifaceted implementation strategy, SEMM-DIA. This includes elements like 1) A program orientation session (virtual or in-person), 2) Technical Assistance for implementers, such as SEMM Program Manager/ Coordinator and LHWs, 3) SEMM program materials (including LHW Training curriculum, in-reach/ outreach materials, patient tracking forms), and 4) Virtual community support (Project ECHO series).; Other Names: SEMM-DIA
Active Comparator: Salud en Mis Manos - Usual Implementation Practice; The SEMM-Usual Implementation Practice arm includes all existing SEMM program materials.	Behavioral: Salud en Mis Manos- Usual Implementation Practice; The control arm will undertake SEMM- Usual Implementation Practice, which includes utilizing all existing SEMM program materials (MOPs, LHW Training Curriculum, etc.) which will be shared with clinic staff in PDF form.; Other Names: SEMM

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reach is measured by the proportion of women who participate in SEMM education sessions among those that are eligible in the clinic (among all eligible patients) & in the community (the number of participants that receive SEMM education).	Reach will assess several factors: Among eligible women, what number participate in SEMM education sessions?	4-month follow up
Reach is measured by the proportion of women who participate in SEMM education sessions among those that are eligible in the clinic (among all eligible patients) & in the community (the number of participants that receive SEMM education).	Reach will assess several factors: Among eligible women, what number participate in SEMM education sessions?	8-month follow up
Effectiveness (for screening) as measured by the percentage of women who complete mammogram screening among all eligible patients.	Investigators will assess mammogram completion outcomes using EHR data collection. All participants identified as eligible for a mammogram between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	Baseline
Effectiveness (for screening) as measured by the percentage of women who complete mammogram screening among all eligible patients.	Investigators will assess mammogram completion outcomes using EHR data collection. All participants identified as eligible for a mammogram between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	4-month follow-up
Effectiveness (for screening) as measured by the percentage of women who complete mammogram screening among all eligible patients.	Investigators will assess mammogram completion outcomes using EHR data collection. All participants identified as eligible for a mammogram between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	8-month follow-up
Effectiveness (for screening) as measured by the percentage of women who complete cervical cancer screening (Pap or HPV screening test) among all eligible patients.	Investigators will assess Pap completion outcomes using EHR data collection. All participants identified as eligible for a Pap or HPV screening test between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	Baseline
Effectiveness (for screening) as measured by the percentage of women who complete cervical cancer screening (Pap or HPV screening test) among all eligible patients.	Investigators will assess Pap completion outcomes using EHR data collection. All participants identified as eligible for a Pap or HPV screening test between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	4-month follow-up
Effectiveness (for screening) as measured by the percentage of women who complete cervical cancer screening (Pap or HPV screening test) among all eligible patients.	Investigators will assess Pap completion outcomes using EHR data collection. All participants identified as eligible for a Pap or HPV screening test between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	8-month follow-up
Effectiveness (for HPV vaccination) as measured by the percentage of female patients who initiate or complete an HPV vaccination among all eligible patients.	Investigators will assess HPV vaccination initiation or completion outcomes using EHR data collection. All participants identified as eligible for an HPV vaccination between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	Baseline
Effectiveness (for HPV vaccination) as measured by the percentage of female patients who initiate or complete an HPV vaccination among all eligible patients.	Investigators will assess HPV vaccination initiation or completion outcomes using EHR data collection. All participants identified as eligible for an HPV vaccination between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	4-month follow-up
Effectiveness (for HPV vaccination) as measured by the percentage of female patients who initiate or complete an HPV vaccination among all eligible patients.	Investigators will assess HPV vaccination initiation or completion outcomes using EHR data collection. All participants identified as eligible for an HPV vaccination between program implementation start and end (regardless if identified via in-reach or outreach) will serve as the denominator.	8-month follow-up
The level of Implementation will be assessed the extent to which SEMM has been carried out per clinic. (1)	Investigators will assess the level of implementation from baseline to 8-month follow-up using manager assessments.	8-month follow-up
The level of Implementation will be assessed the extent to which SEMM has been carried out per clinic. (2)	Investigators will assess the level of implementation from baseline to 8-month follow-up using LHW assessments.	8-month follow-up
The level of Implementation will be assessed the extent to which SEMM has been carried out per clinic. (3)	Investigators will assess the level of implementation from baseline to 8-month follow-up using in-depth end-of-study interviews with LHWs.	8-month follow-up
The level of Implementation will be assessed the extent to which SEMM has been carried out per clinic. (4)	Investigators will assess the level of implementation from baseline to 8-month follow-up using in-depth end-of-study interviews with managers.	8-month follow-up
Implementation (fidelity) as measured by the degree to which SEMM program components are implemented by LHWs as prescribed.	Investigators will assess implementation fidelity using participant tracking forms (completed by LHWs) to understand their level of fidelity associated with implementing the program.	4-month follow-up
Implementation (fidelity) as measured by the degree to which SEMM program components are implemented by LHWs as prescribed.	Investigators will assess implementation fidelity using end-of-study in-depth interviews with LHWs to understand their level of fidelity associated with implementing the program.	8-month follow-up
Implementation dose is described as the average dose of SEMM received by participants/delivered by LHWs (time spent in education sessions).	Investigators will assess implementation dose using SEMM participant tracking forms collected for SEMM participants, which record time spent in education sessions.	4-month follow up
Implementation dose is described as the average dose of SEMM received by participants/delivered by LHWs (# of navigation calls).	Investigators will assess implementation dose using SEMM participant tracking forms collected for SEMM participants, which record # of navigation calls needed to overcome barriers to complete needed services (mammogram, Pap/HPV test, and HPV vaccination).	4-month follow up
Implementation dose is described as the average dose of SEMM received by participants/delivered by LHWs (time spent in education sessions).	Investigators will assess implementation dose using SEMM participant tracking forms collected for SEMM participants, which record time spent in education sessions.	8-month follow up
Implementation dose is described as the average dose of SEMM received by participants/delivered by LHWs (# of navigation calls).	Investigators will assess implementation dose using SEMM participant tracking forms collected for SEMM participants, which record # of navigation calls needed to overcome barriers to complete needed services (mammogram, Pap/HPV test, and HPV vaccination).	8-month follow up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cost effectiveness of SEMM-DIA in community and clinic practice settings	The purpose of the economic analysis is to produce information on the cost-effectiveness of SEMM-DIA in community and clinic practice settings. Investigators will determine the current market value of all ingredients associated with the planning and implementation of the dissemination interventions (from study start to 8-month follow-up), including training and other costs of adapting the intervention to specific sites.	8-month follow up

Collaborators and Investigators

• Sponsor: The University of Texas Health Science Center, Houston
• Collaborators: Centers for Disease Control and Prevention
• Investigators: Principal Investigator: Maria E Fernandez, PhD, The University of Texas Health Science Center, Houston; Principal Investigator: Lara Savas, PhD, The University of Texas Health Science Center, Houston

Study record dates

Study Major Dates

• Study Start (Estimated): February 2, 2024
• Primary Completion (Estimated): September 29, 2024
• Study Completion (Estimated): September 30, 2024

Study Registration Dates

• First Submitted: August 23, 2022
• First Submitted That Met QC Criteria: August 29, 2022
• First Posted (Actual): September 1, 2022

Study Record Updates

• Last Update Posted (Actual): December 1, 2023
• Last Update Submitted That Met QC Criteria: November 30, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Keywords: Breast Cancer; Cervical Cancer; HPV Vaccination; Implementation Intervention
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Uterine Cervical Neoplasms
• Other Study ID Numbers: HSC-SPH-20-1117

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No